Merck & Co. (MRK)$122.41
Market Cap: 208.46 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Merck & Co. (MRK).
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
DCF ready
Valuation
15.7x
EV/FCF, 6.4% FCF yield
Quality
34.7%
ROIC, 19.0% FCF margin
Growth
9.4%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 1.5x current ratio
Superinvestors
9
Top: Kahn Brothers Group (4.8%)
Strengths to research
- Revenue compounded at 9.4% over five years.
- Free cash flow compounded at 16.2% over five years.
- Return on equity is strong at 34.7%.
- Free cash flow margin is healthy at 19.0%.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for MRK.
Grade C
57
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| MRK Target | Merck & Co. | $208.5B | 16.8x | 15.7x | 34.7% | 9.4% | 19.0% | N/A | N/A | N/A |
| NVS | Novartis AG | $223.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHVF | Roche Holdings AG DIV RT | $263.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHBY | Roche Holding AG ADR | $265.2B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| AMGN | Amgen | $150.6B | 23.8x | 24.2x | 12.2% | 7.6% | 22.0% | N/A | 3.2x | N/A |
| NVO | Novo Nordisk A S | $305.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| PFE | Pfizer Inc. | $135.4B | 19.0x | 14.8x | 9.0% | 8.5% | 14.5% | N/A | N/A | N/A |
| SNY | Sanofi Aventis | $133.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| GILD | Gilead Sciences | $128.0B | 19.8x | 15.4x | 17.9% | 3.6% | 32.1% | N/A | 1.7x | N/A |
Financial Charts
No financial data available for MRK (annual).
9 superinvestors own MRK
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Bill Nygren Oakmark Select Fund | 12,366,933 | $1.5B | 1.99% | 0.0% |
| Kahn Brothers Group Kahn Brothers Group | 227,288 | $27M | 4.85% | 0.0% |
| Prem Watsa Fairfax Financial Holdings | 172,900 | $21M | 1.07% | 0.0% |
| Dodge & Cox Dodge & Cox | 136,050 | $16M | 0.01% | 0.0% |
| Mairs & Power Growth Fund Mairs & Power Growth Fund | 50,348 | $6M | 0.06% | 0.0% |
| Christopher Bloomstran Semper Augustus | 44,633 | $5M | 0.64% | 0.0% |
| Richard Pzena Hancock Classic Value | 2,511 | $302,000 | 0.00% | 0.0% |
| Thomas Russo Gardner Russo & Quinn | 2,141 | $258,000 | 0.00% | 0.0% |
| David Katz Matrix Asset Advisors | 1,671 | $201,000 | 0.02% | 0.0% |